Introduction
High serum levels of low-density lipoprotein-cholesterol (LDL-C) have been clearly linked to the risk of cardiovascular disease (CVD). As a result of the high prevalence of undesirable cholesterol levels, this risk factor may account for a large proportion of CVDs in European countries. Despite the rather short period of intervention trials (usually <5 years), a 10% reduction in LDL-C either with a dietary approach or with lipid lowering agents is associated with a 25% reduction of the incidence of coronary artery disease [1] . Lifetime reductions in serum LDL-C levels with adequate diet may therefore have a huge impact on CVD at population's levels. Indeed, lifetime reductions of LDL-C are associated with a dramatic decrease (À88%) in cardiovascular risk as shown in patients having a loss-of-function PCSK9 gene mutation [2] . Furthermore, a large study conducted in the US population demonstrated that a major decline (44%) of deaths from coronary heart disease (CHD) could be attributed to changes in risk factors. Interestingly, 24% of the decrease in coronary deaths was due to a 6% reduction in total cholesterol [3] . As a consequence, a long-term dietary approach would be a unique opportunity to significantly decrease CHD risk throughout a lifetime.
In this review, we summarize the different dietary interventions able to decrease LDL-C. These interventions can also be combined (when appropriate) with weight loss and increased physical activity with a further decrease LDL-C by up to 5%. When looked at individually, each dietary recommendation has a rather small impact especially if long-term compliance is taken into account. However, when combined together in a comprehensive way, dietary changes may have a significant impact on LDL-C and subsequently on CHD risk. Therefore, lifestyle recommendations should be given as early as possible.
Replacing dietary saturated fatty acid by polyunsaturated fatty acid (mainly n À 6) is efficient in decreasing plasma concentration of cholesterol [4 ] . In a meta-analysis of 72 metabolic ward studies of solid food diets in healthy volunteers, Clarke et al. [5] observed that replacement of 5% calories as saturated fatty acid by polyunsaturated fatty acid led to a À0.39 mmol/l change in total blood cholesterol. Similarly, replacing 6.4% of energy as saturated fatty acid by n À 6 polyunsaturated fatty acid while keeping total fat content at 30-33% of energy led to a 22% decrease in plasma LDL-C (À0.63 mmol/l) [6] .
In the Nurse's Health Study, Hu et al. [7] found that polyunsaturated fatty acid intake was inversely associated with CHD risk, with the highest quintile corresponding to a daily intake of 6.4% of energy. The authors concluded that replacing 5% of energy from saturated fatty acid with energy from monounsaturated and polyunsaturated fatty acids would reduce CHD risk by 42% and would be more effective in preventing CHD than reducing overall fat intake.
Trans fatty acids have been used in food manufacturing for a long time partly because of their melting point at room temperature situated between saturated and unsaturated fats which provides favorable texture and mouth feel [8] . However, these fatty acids increase LDL-C and decrease high-density lipoprotein-cholesterol (HDL-C). Furthermore, increasing epidemiologic and biochemical evidence suggest that trans fatty acid-rich diets are a significant risk factor for cardiovascular events [9] . Thus, the American Heart Association recommends limiting trans fats to less than 1% energy. As a result, step 1 and step 2 diets should also include a reduction of trans fatty acid intake.
Whether some fatty acids might be associated with a better risk factor profile is a matter of intensive research. For example, stearic acid, when compared to other saturated fatty acids, lowered LDL-C but is neutral with respect to HDL-C [10 ] . In the opposite, in comparison with unsaturated fatty acids, stearic acid tends to raise LDL-C, lower HDL-C, and increase the ratio of total cholesterol to HDL-C. However, it would premature and difficult to implement these possible subtle differences between saturated fatty acids in clinical practice.
The most recent meta-analysis by Mozaffarian et al. [10 ] systematically investigated and quantified the effects of increased polyunsaturated fatty acid consumption, as a replacement for saturated fatty acid, on CHD endpoints in randomized controlled trials. Studies were included if they randomized participants to increased polyunsaturated fatty acid for at least 1 year without any concomitant major interventions, if they had an appropriate control group and if they reported incidence of CHD. Eight trials met inclusion criteria (13 614 participants with 1042 CHD events). Average weighted polyunsaturated fatty acid consumption was 14.9% energy in intervention groups vs. 5.0% energy in controls. The overall pooled risk reduction was 19% [RR ¼ 0.81, 95% confidence interval (CI) 0.70-0.95, P ¼ 0.008], corresponding to a 10% reduced CHD risk (RR ¼ 0.90, 95% CI 0.83-0.97) for each 5% of polyunsaturated fatty acid energy increase. Meta-regression identified study duration as an independent determinant of risk reduction (P ¼ 0.017), with studies of longer duration showing greater benefits. Altogether, these data indicate that the highest level of evidence in dietary recommendation is the replacement of saturated fatty acid by polyunsaturated fatty acid [11] .
Dietary fibers
Increased dietary fiber intakes are associated with lower prevalence of CVD in prospective studies [11] . Soluble fibers, when included within a saturated fat and cholesterol poor diet, lower LDL-C concentration of about 5-10% in hypercholesterolemic and diabetic patients [12, 13] . In a recent study in patients with mild-to-moderate hypercholesterolemia, a 14 g daily administration of Plantago ovata husk (Po-husk) during 8 weeks induced a mean reduction of 6.1% in LDL-C plasma concentration [14] . A significant lowering (16%) of plasma triglycerides was also observed. Additionally, Po-husk lowered the concentration of oxidized LDL in plasma; a commonly used marker of oxidative damages involved in CHD. Other fibers such as beta-glucan from barley and oat have similar effects on LDL-C. Beyond LDL-C lowering, fibers intake may also have other effects, such as reduction of systolic blood pressure, decrease of body weight and better control of diabetes mellitus [15, 16] . The results of these studies support the routine use of soluble fibers in the recommended diets for adults with hypercholesterolemia. Patients can consume a variety of soluble fibers, beta-glucan, psyllium, pectin, and guar gum as part of their diet.
Plant sterols
Plant sterols are plant compounds that have chemical structures similar to cholesterol. Absorption efficiency of plant sterols in humans is considerably less than the one of cholesterol [17] . Among the different plant sterols, the most abundant are sitosterol, campesterol, and stigmasterol. The daily dietary intake of plant sterols differs among populations and is low to efficiently decrease LDL-C.
A meta-analysis of randomized controlled trials in adults was performed to establish a continuous dose-response relationship that would allow predicting the LDL-C lowering efficacy of different phytosterol doses [18 ] . Eighty-four trials including 141 trial arms were analyzed. The pooled LDL-C reduction was 0.34 mmol/l (95% CI: À0.36, À0.31) or 8.8% (95% CI: À9.4, À8.3) for a mean daily phytosterol dose of 2.15 g. Higher baseline LDL-C concentrations were associated with greater absolute LDL-C reductions. No significant differences were found between the dose-response curves established for plant sterols vs. stanols, fat-based vs. nonfat-based food formats and dairy vs. nondairy foods. There was a strong tendency (P ¼ 0.054) toward a slightly lower efficacy of single vs. multiple daily intakes of phytosterols.
Discussing the effect of plant sterols on atherosclerosis and CVD is beyond the scope of this review. Studies have raised the possibility of circulating plant sterols being a risk factor in the pathogenesis of atherosclerosis. Evidence supporting this hypothesis mainly comes from observations in sitosterolemic patients, who hyperabsorb plant sterols and may suffer premature atherosclerosis. Some epidemiological studies have suggested an increased vascular risk linked to small increases in plasma plant sterol concentrations. However, other prospective and more recent large population-based studies did not confirm these earlier results. Furthermore, the potential (and highly hypothetical) risk of plant sterol-enriched foods may be counterbalanced by the notable reduction in plasma LDL-C.
Among the therapeutic lifestyle changes aiming to reduce CHD risk, plant stanol or sterol-enriched products consumption is now recommended to achieve the necessary LDL-C lowering. Plant sterols and stanols are recommended by the American Heart Association and the European Food Safety Authority which stated that 'a clinically significant LDL-C lowering effect of about 9% can be achieved by a daily intake of 2-2.4 g of phytosterols in an appropriate food'.
Nuts consumption
Frequent nut consumption has been found to be protective against CHD in five large epidemiological studies [19 ,20] . A qualitative summary of the data from four of these studies found an 8.3% reduction in risk of death from CHD for each weekly serving of nuts. Despite the fact that double-blind placebo-controlled studies are impossible to conduct, more than 40 dietary intervention studies have evaluated the effect of nut containing diets on blood lipids. Even in the context of healthy diets, these studies in healthy study participants or patients with moderate hypercholesterolemia have demonstrated that intake of different kinds of nuts lowers LDL-C, total cholesterol as well as the LDL : HDL ratio. The exact underlying mechanisms remain to be established. Nuts have a unique fatty acid profile and feature a high unsaturated to saturated fatty acid ratio. Additional potential cardioprotective nutrients are found in nuts: vegetable protein, fibers, alpha-tocopherol, folic acid, magnesium, copper, phytosterols and other phytochemicals. Interestingly, adding nuts to diets does not seem to be associated with weight gain, possibly due to the increased satiety induced by nut consumption.
Soy protein/isoflavone
In 1995 Anderson et al. [21] analyzed 38 controlled clinical studies among which 30 were conducted in hypercholesterolemic patients. Compared with animal protein, a mean intake of 47 g/day of isolated or textured soy protein resulted in a significant reduction in LDL-C (12.9%) and in triglycerides (10.5%) without significant changes in HDL-C levels. Therefore, the Food and Drug Administration approved a food-labelling health claim for soy protein in the prevention of CHD. More recent results found inconsistencies. Indeed, mean consumption of 50 g/day (ranging from approximately 25 to 133 g) of isolated soy protein, lowered LDL-C levels by only 3% in comparison with milk or other proteins. The studies did not address possible mechanisms of the effects of soy protein intake [22, 23] . Whether the changes were attributable to the soy protein per se, other soy-derived factors (constitutive isoflavones), or both remained to be established. Altogether, these data suggest that soy protein/ isoflavones are possible but uncertain components to use in the global strategy of dyslipidemic patients treatment.
Portfolio diet
As the use of soy protein, viscous dietary fibers and nuts are supposed to enhance the cholesterol-lowering effectiveness of a diet, a dietary portfolio containing all of these recommended food components known to decrease LDL-C was tested in hyperlipidemic adults in a randomized controlled trial [24, 25] . The study was conducted in 46 healthy, hyperlipidemic adults. Participants were randomly assigned to undergo one of the three following interventions on an outpatient basis for 1 month: a very saturated fat poor diet, based on milled whole-wheat cereals and low-fat dairy foods (n ¼ 16; control group); the same diet plus a 20-mg lovastatin daily dose (n ¼ 14, statin group); or a diet rich in plant sterols (1.0 g/ 1000 kcal), soy proteins (21.4 g/1000 kcal), viscous fibers (9.8 g/1000 kcal), and almonds (14 g/1000 kcal) (n ¼ 16; dietary portfolio group). The control, statin, and dietary portfolio groups had mean (SE) decreases in LDL-C of 8.0% (2.1%) (P ¼ 0.002), 30.9% (3.6%) (P < 0.001), and 28.6% (3.2%) (P < 0.001), respectively. There were no significant differences in efficacy between the statin and Lowering LDL-cholesterol through diet Bruckert and Rosenbaum 45 dietary portfolio treatments. Interestingly, this significant effect was confirmed in a longer 12-month study [26] . The main message for clinicians is that the different diet recommendations used in these studies are complementary (i.e., additive or synergistic) in their effect on serum LDL-C. A large study assessing the impact of such strategy on atherosclerosis or cardiovascular events would be most interesting.
Mediterranean diet
The term 'Mediterranean diet' is well understood but not clearly defined because it is a comprehensive approach which includes most of recommendations given in the step 1 and step 2 diets with an addition of higher fiber intake through an increase in fruit and vegetable consumption together with nuts. Detailed analysis of the effect of this diet on risk factors and cardiovascular risk is beyond the scope of this manuscript. However, it is of interest to mention the cumulative analysis among eight cohorts (514 816 study participants and 33 576 deaths) evaluating overall mortality in relation to adherence to a Mediterranean diet. It showed that a two-point increase in the adherence score was significantly associated with a reduced risk of mortality (pooled relative risk 0.91, 95% CI 0.89-0.94). Likewise, this analysis showed a beneficial role for greater adherence to a Mediterranean diet on cardiovascular mortality (pooled relative risk 0.91, 95% CI 0.87-0.95). Another systematic review was made with 35 different intervention studies [27] . The Mediterranean diet showed favorable effects on lipoprotein levels, endothelium vasodilatation, insulin resistance, metabolic syndrome, antioxidant capacity, myocardial and cardiovascular mortality. The Mediterranean diet has also favorable effects on obesity and type 2 diabetes. Both epidemiological and interventional studies have revealed a protective effect of the Mediterranean diet against mild chronic inflammation and its metabolic complications [28, 29] . As a consequence, this popular way of explaining to the patient what a healthy diet might be is an attractive tool in current practice. A difficult question is whether this diet should include more omega-6 fatty acid (confer paragraph on step 1 and step 2 diet) or be more 'olive oil' centered.
Increasing long-term compliance
As shown above, the goal of reducing cholesterol and improving risk factors in hypercholesterolemic patients can be reached through improvement, even subtle, of food habits. However, patients' adherence and compliance to dietetic prescription are essential to 'make it work' but difficult to obtain. To improve adherence, physicians should identify possible barriers and seek for adequate levers to overcome these barriers. Several barriers to adherence have been identified among which: the false perception by both physicians and patients, that diet has poor efficacy; inappropriate evaluation of cardiovascular risk; lack of time; and a demand of practical information. Obviously, proper information on efficacy and referring to a dietician should help provide practical information expected by our patients.
Diet and lipid-lowering agents
Generally speaking, both strategies should be combined when a statin prescription is recommended according to local guidelines. All large intervention studies have been conducted in patients following a step 1 or step 2 diet even if the reality of adherence was poorly assessed. In practice, there are few interactions between dietary recommendation and statin use [30 ] . The most relevant one is the pharmacokinetic changes with statins metabolized by the cytochrome P450 with grapefruit juice. Concomitant consumption of certain foods can lead to a modest reduction (in the case of fibers) or a slight increase (n À 3 fatty acids, phytosterols) of the statins' pharmacological actions.
Addendum on recent finding with marine omega-3 fatty acids
Both eicospentenoic and docohexenoic acids, the marine omega-3 polyunsaturated fatty acids have been extensively studied to assess their role in prevention of CVD. These studies were stimulated by early observation that the Greenland Inuit population had low risk of CHD. These products have pleiotropic effects on the cardiovascular system with little if any risk of adverse events [31 ] .
Meta-analyses of randomized controlled studies failed to achieve a straightforward conclusion regarding the effect on reduction of events possibly due to quality heterogeneity in studies included. The most recent one included 29 trials with 35 144 subjects. It showed that omega-3 fatty acid intake was not associated with a statistically significant decrease of mortality (RR 0.88; 95% CI 0.64-1.03) in high-risk patients [32 ] . There is, however, strong indication for a reduction in coronary events and sudden coronary death mostly in secondary prevention [33] . The impact of omega-3 fatty acid in primary prevention remains to be established although a reduction of event was observed in the JELIS trial [34] . Altogether, these data do not support wide utilization of high-dose omega-3 food supplement to prevent cardiovascular event.
In this context, a large randomized placebo-controlled study tested the effect of 400 mg of eicospentenoic and docohexenoic acids or 2 g of alpha linolenic fatty acid or both in 4837 patients who had a myocardial infarction [35 ] . The study failed to achieve a significant reduction in the primary event. Importantly, this recent study included patients with the state-of-the-heart treatment of their medical condition. This well conducted and recent study does not support wide utilization of lowdose supplement to prevent cardiovascular events in secondary prevention.
The effect of marine omega-3 fatty acids on lipid parameters is characterized by a decrease of serum triglyceride levels observed only at high dose (up to 4 g/l), but there is almost no effect on LDL-C. These high dosages have not been studied in randomized controlled trials with cardiovascular outcome.
Despite the controversial results obtained in trials with omega-3 fatty acids, it is usually recommended to consume fish at least twice a day as part of a 'healthy diet'. Unlike food supplement, such intake usually replaces meat consumption and is associated with a reduction in saturated fats.
Conclusion
We have briefly reviewed the different dietary approaches able to lower LDL-C in dyslipidemic patients. These recommendations should be combined with other changes in lifestyle such as smoking cessation, increased physical activity and weight loss when appropriate. In practice, the recommendations provided by physicians also need to emphasize the interest of omega-3-rich foods (not described here due to the lack of effect on LDL-C). They also need to be implemented in a very practical and 'down to earth' way (e.g., eating fruits and vegetables not dietary fiber) and to take into account their cost for patients with low income.
